Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Selegiline transdermal - Somerset Pharmaceuticals

Next Previous
X
Search
Drug Profile

Selegiline transdermal - Somerset Pharmaceuticals

Alternative Names: Emsam

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Somerset Pharmaceuticals
  • Class Analgesics; Antidementias; Antidepressants; Antiparkinsonians; Phenethylamines; Small molecules
  • Mechanism of Action Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Major depressive disorder
  • No development reported Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders; Parkinson's disease

Most Recent Events

  • 29 May 2009 Selegiline is no longer licensed to Bristol-Myers Squibb in USA; Dey LP aquires marketing rights
  • 28 Jul 2008 Somerset Pharmaceuticals has become a wholly owned subsidiary of Mylan Inc.
  • 08 May 2008 Efficacy data from a post-hoc analysis in Depression presented at the 161st Annual Meeting of the American Psychiatric Association (APA-2008)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top